For example, a decrease in CPT1a expression, coupled with enhanced long-chain acyl-CoA dehydrogenase (LCAD) and HADH mRNAs levels, was detected in liver biopsies from patients with non-alcoholic fatty liver disease [56]. This evidence concerns the gene ACADL and metabolic dysfunction-associated steatotic liver disease.